Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
PaperCitations, authors & open-access status
LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 83 citations, 2023 year and bronze oa status.
83
Citations
2023
Year
bronze
OA Status